公开(公告)号：US20150071854A1

公开(公告)日：2015-03-12

申请号：US14490328

申请日：2014-09-18

Applicant: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. ,  The Government of the United States of America, as represented by the Secretary, Department of Healt

Inventor： Dimiter S. Dimitrov ,  Zhongyu Zhu ,  Christopher C. Broder

IPC: C07K16/12 ,  G01N33/569 ,  A61K51/10

CPC classification number: C07K16/1203 ,  A61K51/1009 ,  A61K2039/505 ,  C07K16/1027 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N33/6893 ,  G01N2333/115 ,  G01N2469/10

Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

公开(公告)号：US20140273022A1

公开(公告)日：2014-09-18

申请号：US13828554

申请日：2013-03-14

Applicant: Silver Lake Research Corporation

Inventor： Robert K. DiNello ,  Mark Geisberg

IPC: G01N33/569

CPC classification number: G01N33/56911 ,  C07K16/1203 ,  C07K16/1232 ,  C07K2317/30 ,  C07K2317/34 ,  G01N33/56916 ,  G01N33/56922 ,  G01N33/56927 ,  G01N33/56933 ,  G01N33/56938 ,  G01N33/56944 ,  G01N33/5695 ,  G01N33/6854

Abstract: In some aspects, provided are methods relating to the use of bacterial N-methyl-2 superfamily proteins as a biomarker for the presence of bacteria in a sample. The invention also relates to novel methods of diagnosis of the presence of bacteria in a liquid or solid sample, detection of bacterial infections in humans or animals, and use of antibodies or other specific binding molecules capable of binding to N-methyl-2 superfamily proteins.

Abstract translation: 在一些方面，提供了关于使用细菌N-甲基-2超家族蛋白作为样品中细菌存在的生物标志物的方法。 本发明还涉及诊断液体或固体样品中细菌存在的新方法，检测人或动物中的细菌感染，以及使用能够结合N-甲基-2超家族蛋白的抗体或其它特异性结合分子 。

公开(公告)号：US20140182003A1

公开(公告)日：2014-06-26

申请号：US14056434

申请日：2013-10-17

Applicant: Kymab Limited

Inventor： Allan Bradley ,  E-Chiang Lee ,  Qi Liang ,  Wei Wang ,  Anais Legent ,  Ian Kirby

IPC: A01K67/027

CPC classification number: A01K67/0278 ,  A01K67/0271 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A61K39/107 ,  A61K39/35 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/1203 ,  C07K16/1239 ,  C07K16/18 ,  C07K16/462 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/8509 ,  C12N2015/8518

Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

公开(公告)号：US20140148592A1

公开(公告)日：2014-05-29

申请号：US14171305

申请日：2014-02-03

Applicant: A. Stewart CAMPBELL ,  Gregory LOHMAN ,  Obadiah J. PLANTE

Inventor： A. Stewart CAMPBELL ,  Gregory LOHMAN ,  Obadiah J. PLANTE

IPC: C07H3/06

CPC classification number: A61K39/1045 ,  A61K2039/6081 ,  C07H3/06 ,  C07H15/04 ,  C07H15/26 ,  C07K16/1203 ,  C07K19/00 ,  C07K2317/14 ,  C07K2317/20 ,  C07K2317/21 ,  G01N33/56911 ,  G01N2333/212

Abstract: The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis oligosaccharide structures or motifs corresponding to one or more of the three major serotypes and/or members within a given serotype. The oligosaccharides may be synthesized by a chemical assembly methodology relying on a limited number of monosaccharide and disaccharide building blocks. The invention further provides M. catarrhalis LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by M. catarrhalis.

Abstract translation: 本发明提供合成的莫拉卡氏菌属低密度脂多糖（LOS）基寡糖和含有各种卡他莫拉胺血清型特异性寡糖抗原或各种核心卡他莫拉低聚糖结构或缀合物的缀合物，其对应于三种主要血清型和/或成员中的一种或多种 在给定的血清型。 寡糖可以通过依靠有限数量的单糖和二糖结构单元的化学组装方法来合成。 本发明进一步提供基于粘膜炎的基于LOS的免疫原性和免疫保护组合物及其衍生的抗体用于诊断，治疗和预防卡他莫拉菌引起的感染。

公开(公告)号：US20140134156A1

公开(公告)日：2014-05-15

申请号：US14137902

申请日：2013-12-20

Applicant: Kymab Limited

Inventor： Allan Bradley ,  E-Chiang Lee ,  Qi Liang ,  Wei Wang ,  Anais Legent ,  Ian Kirby

IPC: A01K67/027 ,  C07K16/18 ,  C07K16/12

CPC classification number: A01K67/0278 ,  A01K67/0271 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A61K39/107 ,  A61K39/35 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/1203 ,  C07K16/1239 ,  C07K16/18 ,  C07K16/462 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/8509 ,  C12N2015/8518

Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

Abstract translation: 本发明公开了产生嵌合人非 - 人抗体和嵌合抗体链，如此产生的抗体和抗体链的方法及其衍生物，包括完全人源化抗体; 包含适合用于所述方法的所述抗体，抗体链和衍生物的组合物，以及细胞，非人哺乳动物和载体。

公开(公告)号：US20140120582A1

公开(公告)日：2014-05-01

申请号：US14080630

申请日：2013-11-14

Applicant: Kymab Limited

Inventor： Allan Bradley ,  E-Chiang Lee ,  Qi Liang ,  Wei Wang ,  Anais Legent ,  Ian Kirby

IPC: A01K67/027

CPC classification number: A01K67/0278 ,  A01K67/0271 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A61K39/107 ,  A61K39/35 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/1203 ,  C07K16/1239 ,  C07K16/18 ,  C07K16/462 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/8509 ,  C12N2015/8518

Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

公开(公告)号：US08575425B2

公开(公告)日：2013-11-05

申请号：US12828594

申请日：2010-07-01

Applicant: Nalini Manoj Desai ,  Jill Hinson ,  Deepa Balasubramanian ,  Kimberly S. Sampson ,  Daniel J. Tomso ,  Duane Alan Lehtinen ,  Nicholas Duck ,  Rong Guo ,  Volker Heinrichs

Inventor： Nalini Manoj Desai ,  Jill Hinson ,  Deepa Balasubramanian ,  Kimberly S. Sampson ,  Daniel J. Tomso ,  Duane Alan Lehtinen ,  Nicholas Duck ,  Rong Guo ,  Volker Heinrichs

IPC: A01H5/00 ,  C07K14/22 ,  A01N37/18 ,  C12N15/31 ,  C12N15/63 ,  C12N15/82 ,  C12N1/21

CPC classification number: C07K14/195 ,  C07K14/22 ,  C07K16/1203 ,  C12N15/8285 ,  C12N15/8286 ,  C12Q1/6876 ,  Y02A40/162 ,  Y02A40/164

Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for pesticidal polypeptides are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated pesticidal nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2, 3, or 4, the nucleotide sequence set forth in SEQ ID NO:1, 9, 10, or 11, as well as variants and fragments thereof.

Abstract translation: 提供了赋予细菌，植物，植物细胞，组织和种子的杀虫活性的组合物和方法。 提供了包含杀虫多肽的编码序列的组合物。 编码序列可用于DNA构建体或表达盒中，用于在植物和细菌中转化和表达。 组合物还包括转化的细菌，植物，植物细胞，组织和种子。 特别地，提供了分离的杀虫核酸分子。 另外，包括对应于多核苷酸的氨基酸序列。 特别地，本发明提供了包含编码SEQ ID NO：2,3或4所示氨基酸序列的核苷酸序列的核酸分子，SEQ ID NO：1,9,10或11所示的核苷酸序列 ，以及其变体和片段。

公开(公告)号：US08420783B2

公开(公告)日：2013-04-16

申请号：US11296432

申请日：2005-12-08

Applicant: David M. Goldenberg ,  Hans J. Hansen

Inventor： David M. Goldenberg ,  Hans J. Hansen

IPC: C07K16/00

CPC classification number: A61K39/3955 ,  A61K31/513 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/4866 ,  A61K39/40 ,  A61K45/06 ,  A61K49/0002 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/1203 ,  C07K16/24 ,  C07K16/241 ,  C07K16/248 ,  C07K16/2803 ,  C07K16/2896 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/734

Abstract: Methods and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases, using multispecific antagonists that target at least two different markers are disclosed. The different targets include proinflammatory effectors of the innate immune system and targets specifically associated with an inflammatory or immune-dysregulatory disorder, wherein the targets included in the latter group are not a proinflammatory effector of the immune system. Thus, the multispecific antagonist contains at least one binding specificity related to the diseased cell or condition being treated and at least one specificity to a component of the immune system. The multispecific antagonists are used in the treatment of various diseases that are generated or exacerbated by, or otherwise involve, proinflammatory effectors of the innate immune system.

Abstract translation: 公开了使用靶向至少两种不同标记的多特异性拮抗剂的炎性和免疫调节性疾病的免疫治疗的方法和组合物。 不同的靶标包括先天免疫系统的促炎效应物和与炎症或免疫调节障碍特异性相关的靶标，其中包括在后一组中的靶标不是免疫系统的促炎效应物。 因此，多特异性拮抗剂含有与待治疗的病变细胞或病症相关的至少一种结合特异性，并且对免疫系统的组分具有至少一种特异性。 多特异性拮抗剂用于治疗由天然免疫系统的促炎症作用者产生或加剧或以其他方式涉及的各种疾病。

公开(公告)号：US20130011400A1

公开(公告)日：2013-01-10

申请号：US13412218

申请日：2012-03-05

Applicant: Keith Alan Charlton ,  Andrew Justin Radcliffe Porter ,  Ian Broadbent

Inventor： Keith Alan Charlton ,  Andrew Justin Radcliffe Porter ,  Ian Broadbent

IPC: A61K39/40 ,  A61P31/04 ,  C07K16/12

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K16/1203 ,  C07K16/1214 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/73

Abstract: The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to Pseudomonas aeruginosa infection, for example in the treatment of pulmonary infection in cystic fibrosis patients, and represent a unique bactericidal medication that does not directly target the bacteria.

Abstract translation: 本发明涉及通过调节细菌细胞信号分子的细胞外浓度来杀死感染性细菌的方法。 这具有在大多数细菌细胞中诱导快速细胞死亡（自溶）的作用，并且防止存活细胞中的毒力或恢复良性状态。 这些受体具有用于治疗感染易感性，治疗现有感染患者，疾病管理以及感染宿主是动物或植物的相关应用的个体的应用。 本文描述的组合物与铜绿假单胞菌感染特别相关，例如在囊性纤维化患者中治疗肺部感染，并且代表不直接靶向细菌的独特的杀菌药物。

公开(公告)号：US20120165211A1

公开(公告)日：2012-06-28

申请号：US13350527

申请日：2012-01-13

Applicant: Roberto BURIONI ,  Filippo CANDUCCI ,  Massimo CLEMENTI ,  Federico MAISANO

Inventor： Roberto BURIONI ,  Filippo CANDUCCI ,  Massimo CLEMENTI ,  Federico MAISANO

IPC: G01N33/53 ,  G01N33/554 ,  C40B30/04 ,  C07K16/12

CPC classification number: C07K16/18 ,  C07K16/1203 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/55 ,  G01N33/6854 ,  G01N33/6893 ,  G01N2800/323 ,  G01N2800/324

Abstract: The present invention refers to human antibodies derived from human antibody libraries prepared from atherosclerotic plaques. It further refers to human antibodies able to immunologically recognize both human transgelin or fragments thereof and a protein with at least 50% similarity to OmpK36 (Outer membrane protein, Klebsiella, K36; GI: 295881594) or fragments thereof. Human transgelin is preferably transgelin 1 (Accession N° Q01995, GI:48255907). The antibodies further recognize an antigen in the atherosclerotic plaque and are useful for the preparation of immunodiagnostic reagents or assays to detect atherogenic diseases. The invention also relates to the use of anti-TAGLN monoclonal antibodies, showing cross-reactivity with a bacterial antigen having at least 50% similarity with OmpK36, for detecting antigens in the atherosclerotic plaque or as atherosclerotic related reagents in an immuno-competition assay.

Abstract translation: 本发明涉及源自动脉粥样硬化斑块制备的人抗体文库的人抗体。 其还涉及能够免疫识别人类透明质素或其片段的人抗体以及与OmpK36（外膜蛋白，克雷伯氏菌，K36; GI：295881594）或其片段具有至少50％相似性的蛋白质。 人类透明质素优选为透明质素1（登录号：Q01995，GI：48255907）。 抗体进一步识别动脉粥样硬化斑块中的抗原，并且可用于制备免疫诊断试剂或检测致动脉粥样化疾病的测定法。 本发明还涉及使用抗TAGLN单克隆抗体，显示与与OmpK36具有至少50％相似性的细菌抗原的交叉反应性，用于在免疫竞争测定中检测动脉粥样硬化斑块中的抗原或作为动脉粥样硬化相关试剂。